Ads by Google
Patients whose lung cancer has spread to the lymph nodes have a better chance of long term survival if they receive combined modality therapy.
The addition of the monoclonal antibody Bevacizumab (Avastin) to the standard treatment for advanced, non squamous non small cell lung cancer produced improved survival rates.
Surgeons can see lung disease and early signs of cancer that would otherwise be undetectable with a CAT scan, blood test or white light bronchoscopy.
Study reveals complex mechanism underlying resistance to targeted lung cancer drugs.
Finding a new approach that can pinpoint which proteins contribute to malignancy is critical because current approaches we use to diagnose and treat lung cancer have had no significant impact on lung cancer mortality.
Researchers have closed a randomized clinical trial comparing gefitinib (Iressa TM) vs. placebo following chemotherapy and radiation for patients with non small cell lung cancer.
Scientists are developing a non invasive test that could detect lung cancer in its earliest stages, while it is still treatable.
Bevacizumab Combined with Chemotherapy Prolongs Survival for Some Patients with Advanced Lung Cancer
Results from a clinical trial for patients with previously untreated advanced non squamous, non small cell lung cancer show that those patients who received bevacizumab (Avastin) in combination with standard chemotherapy lived longer than patients who received the same chemotherapy without bevacizumab.